Research from Kunming Medical University has uncovered significant links between hormonal imbalances, gut microbiota, and cognitive deficits in patients with pituitary neuroendocrine tumors (PitNETs). These tumors, while often associated with visual disturbances and endocrine issues, are increasingly recognized for their impact on cognitive functions, particularly memory, attention, and executive capabilities. This cognitive decline can severely affect patients’ overall quality of life.
Traditionally, cognitive impairments in these patients have been attributed to the physical presence of tumors and their mass effects. However, an emerging perspective suggests that hormonal dysregulation and gut health might play crucial roles in cognitive dysfunction, prompting researchers to explore these connections further.
Study Overview and Findings
Led by Dr. Xingli Deng, the study involved a cohort of 42 patients with PitNETs, matched against 42 healthy controls. Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA) both prior to and three months following surgical intervention. The researchers meticulously recorded tumor characteristics such as volume and invasiveness via MRI, while also classifying tumors into functional and nonfunctional categories based on molecular lineage (specifically, PIT1 and SF-1).
In a notable finding, patients with PitNETs exhibited significantly lower cognitive performance compared to their healthy counterparts, particularly in areas related to attention, executive function, and memory. This cognitive impairment was especially pronounced in those with functional tumors classified under the PIT1 lineage. Dr. Deng commented on the study’s goals, stating, “By integrating neurocognitive assessment with endocrine profiling and microbiome analysis, we aimed to explore a more comprehensive, biologically grounded model of cognitive dysfunction in PitNET patients.”
Importantly, the study revealed that traditional indicators, such as tumor volume and invasiveness, did not correlate significantly with cognitive outcomes. This challenges the long-held belief that structural mass effects are the primary contributors to cognitive decline in these patients.
Implications of Hormonal and Microbiome Changes
Following surgical tumor removal, improvements in cognitive scores were observed, alongside reductions in elevated hormone levels such as growth hormone (GH), insulin-like growth factor 1 (IGF-1), and prolactin (PRL). These results suggest that hormonal changes may underlie both cognitive dysfunction and recovery, indicating a potential endocrine mechanism at play.
Microbiome analysis further highlighted distinct alterations in gut bacterial composition among PitNET patients. The study found a reduced abundance of Agathobacter, a genus known for its anti-inflammatory properties, while levels of potentially pro-inflammatory taxa, including Alistipes indistinctus, were elevated. Such shifts suggest that inflammatory and metabolic pathways related to gut microbiota may interact with hormonal dysregulation, influencing cognitive outcomes.
The comprehensive nature of this study—integrating clinical, endocrine, cognitive, and microbiome data—marks a significant advancement in understanding cognitive dysfunction among PitNET patients. However, the modest sample size and cross-sectional design of the microbiome analysis highlight the need for further research. Larger longitudinal studies are essential to clarify causality and explore whether interventions targeting gut microbiota can meaningfully enhance cognitive outcomes alongside surgical treatment.
In conclusion, cognitive impairment is prevalent among patients with PitNETs, particularly those with tumors of the PIT1 lineage. The study indicates that cognitive dysfunction is more closely linked to hormonal dysregulation and changes in gut microbiota than to traditional measures of tumor burden. Surgical intervention not only aids in cognitive recovery but also suggests that modulation of the gut-brain axis could offer promising therapeutic avenues for improving neurological function and overall quality of life for these patients.
The findings were published in the Chinese Neurosurgical Journal on December 30, 2025, providing new insights into the multifactorial basis of neurocognitive dysfunction in PitNET patients.
